Proposed Pharmaceutical Affairs Act Amendment Regarding Patent-Approval Linkage System
On August 20, 2020, the Ministry of Food and Drug Safety (‘MFDS’) announced a proposed amendment to the Pharmaceutical Affairs Act (‘PAA’) aimed to address certain deficiencies in the Patent-Approval Linkage System that went into effect in 2015. Key features of the proposed amendment may be summarized as follows.
Aug. 27, 2020
1. Enforcement Rules to Specify Eligibility Criteria for Patent Listing (Article 50-2, Paragraph 6 of the Proposed Amendment)
The current PAA does not clearly explain the requirements for patents to be listed under the Patent-Approval Linkage System, and the lack of clarity has posed difficulties for original drug companies in selecting patents for listing. The proposed amendment addresses this concern by delegating the MFDS to establish enforcement rules to clarify the examination criteria regarding which types of patents may be listed and the eligibility requirements (e.g., the patent be directly relevant to the drug dossiers) and relevant documentation guidelines. Subsequent rulemaking activities therefore are expected and should be monitored.
2. Protection of First Generic Exclusivity Through Restriction on Patent De-listing (Article 50-3, Paragraph 5 of the Proposed Amendment)
Under the current PAA, if a patent is removed from the drug-patent list after first generic exclusivity has been granted, the first generic exclusivity cannot be enforced against follow-on products for which an application for marketing approval has been filed on or after the date of de-listing. The proposed amendment aims to address this concern by restricting de-listing of patents once first generic exclusivity has been applied for until the first generic exclusivity expires.
3. Patent Listing Fee Exemption If De-Listing Is Restricted Due To First Generic Exclusivity (Article 82-2, Paragraph 1 of Proposed Amendment)
Patent listing fee will be waived for any patent that has not been de-listed due to first generic exclusivity despite the market approval holder’s request for de-listing.
4. Clarification of Scope of Follow-On Drugs Subject to First Generic Exclusivity (Article 50-9, Paragraph 1 of the Proposed Amendment)
The proposed amendment clarified that follow-on drugs that will be blocked by first generic exclusivity are those approved on or after the date of application for first generic exclusivity. The proposed amendment aims to address the current PAA’s failure to specify the applicable timing for the sales ban implemented by first generic exclusivity.
The MFDS will receive comments regarding the proposed amendment until October 19, 2020.
Items You Might Have Missed
Sanjo’s “Silent Spring”
Confucius saw music as a device for self-cultivation, a vehicle of self-expression, a force of social stability, a political tool, and a medium of communion between man, nature, and supernatural powers. Psy brings us “Hangover.”
June 9, 2016
Korea’s KFTC At the Crossroads Between Antitrust and Intellectual Property
The KFTC’s recent amendment of its IPR Guidelines is a signal to the world of its increasing sophistication and aggressiveness.
June 9, 2016
Like It Or Not, Korean Companies Face E-Discovery Issues Even In Arbitration
Though changes in the US Federal Discovery Rules as well as case law such as Zubulake have escalated the Electronically Stored Information ( ESI) costs as it relates to electronic discovery or discovery of ESI documents and information (E-Discovery) in the US, Korean companies have remained relatively complacent about it until the Dupont v Kolon case.
June 29, 2016
Longing for a Way of Life We Once Chose to Transform
Two years ago, the world’s biggest IKEA came to Seoul. Larger than the chain’s Stockholm store, its floor space rivals that of the Louvre Museum in Paris.
June 29, 2016
The Strange, Secret, Wondrous Life of Information
We all know information is important to doing business. It has always been so. It is said that the first use of the telescope was to see distant trade ships coming on the horizon and to, thereby, get an edge in negotiating with sellers who were still unaware that additional supply was soon to arrive. More information, better information, equaled business advantage then and it still does today. A good understanding of the nature and tendencies of information would seem to be very valuable in that case. So let’s examine some of the interesting things about information itself both for business in general, and in particular where it applies to predicting what is going to happen next.
June 29, 2016